Immunogenicity and protective efficacy of Yersinia ruckeri lipopolysaccharide (LPS), encapsulated by alginate-chitosan micro/nanoparticles in rainbow trout (Oncorhyncus mykiss)

Dezfuly, Zahra Tulaby; Alishahi, Mojtaba; Ghorbanpoor, Masoud; Tabandeh, Mohammad Reza; Mesbah, Mehrzad

doi:10.1016/j.fsi.2020.05.029

Cited by 19 publications

(12 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Attenuated Brucella melitensis encapsulated in alginate microspheres induces cell-mediated and antibody-mediated immune responses that are greater than freely suspended cells, and was effective at reducing the bacterial burden in mouse tissues [25]. Alginate encapsulation has also been effectively used to stimulate protection against Yersinia ruckeri in rainbow trout [28], Piscirickettsia salmonis in salmon [29], and Bordetella pertussis in mice [30]. Therefore, in theory, when used as a vaccine vehicle alginate encapsulation should prevent the immediate clearance of the attenuated strain, allowing the agent to be slowly released over an extended period of time, and continuously stimulate the immune system.…”

Section: Introductionmentioning

confidence: 99%

Alginate microencapsulation of an attenuated O-antigen mutant of Francisella tularensis LVS as a model for a vaccine delivery vehicle

et al. 2022

View full text Add to dashboard Cite

Francisella tularensis is the etiologic agent of tularemia and a Tier I Select Agent. Subspecies tularensis (Type A) is the most virulent of the four subspecies and inhalation of as few as 10 cells can cause severe disease in humans. Due to its niche as a facultative intracellular pathogen, a successful tularemia vaccine must induce a robust cellular immune response, which is best achieved by a live, attenuated strain. F. tularensis strains lacking lipopolysaccharide (LPS) O-antigen are highly attenuated, but do not persist in the host long enough to induce protective immunity. Increasing the persistence of an O-antigen mutant may help stimulate protective immunity. Alginate encapsulation is frequently used with probiotics to increase persistence of bacteria within the gastrointestinal system, and was used to encapsulate the highly attenuated LVS O-antigen mutant WbtIG191V. Encapsulation with alginate followed by a poly-L-lysine/alginate coating increased survival of WbtIG191V in complement-active serum. In addition, BALB/c mice immunized intraperitoneally with encapsulated WbtIG191V combined with purified LPS survived longer than mock-immunized mice following intranasal challenge. Alginate encapsulation of the bacteria also increased antibody titers compared to non-encapsulated bacteria. These data suggest that alginate encapsulation provides a slow-release vehicle for bacterial deposits, as evidenced by the increased antibody titer and increased persistence in serum compared to freely suspended cells. Survival of mice against high-dose intranasal challenge with the LVS wildtype was similar between mice immunized within alginate capsules or with LVS, possibly due to the low number of animals used, but bacterial loads in the liver and spleen were the lowest in mice immunized with WbtIG191V and LPS in beads. However, an analysis of the immune response of surviving mice indicated that those vaccinated with the alginate vehicle upregulated cell-mediated immune pathways to a lesser extent than LVS-vaccinated mice. In summary, this vehicle, as formulated, may be more effective for pathogens that require predominately antibody-mediated immunity.

show abstract

Section: Introductionmentioning

confidence: 99%

Alginate microencapsulation of an attenuated O-antigen mutant of Francisella tularensis LVS as a model for a vaccine delivery vehicle

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The same study also demonstrated the toxicity of T. maritimum ECPs on artificially infected epithelioma papulosum cyprini cell line and Senegalese sole (Solea senegalensis) fingerlings whereby the cytotoxic effect on the cell line and ulcerative haemorrhagic lesions on fingerlings were observed within 24 h post-challenge. The involvement of ECPs of Tenacibaculum species in causing tenacibaculosis requires further investigation because ECP based vaccination has shown protection against some important bacterial diseases including yersiniosis and streptococcosis [97][98][99][100].…”

Section: Resultsmentioning

confidence: 99%

Experimental challenge of Chinook salmon withTenacibaculum maritimumandTenacibaculum dicentrarchifulfils Koch’s postulates

Kumanan,

Carson,

Hunter

et al. 2024

Preprint

View full text Add to dashboard Cite

The bacterial skin disease tenacibaculosis, caused byTenacibaculumspecies, can compromise numerous species of economically important marine fish, including salmonids. While tenacibaculosis is a known threat to Atlantic salmon (Salmo salar) aquaculture, the pathogenesis ofTenacibaculum maritimumandTenacibaculum dicentrarchion Chinook salmon (Oncorhynchus tshawytscha) has not yet been investigated. In this study, three molecular O-AGC types ofT. maritimum(O-AGC Type 3-0, Type 2-1 and Type 3-2) andT. dicentrarchiisolated during a disease outbreak of farmed Chinook salmon in Aotearoa New Zealand were assessed for their ability to induce tenacibaculosis in salmon smolts under controlled conditions. Naive Chinook salmon were exposed toT. maritimumorT. dicentrarchiby immersion. Clinical signs of tenacibaculosis were apparent post-exposure and observed in 100% of all three molecular O-AGC types ofT.-maritimum-challenged fish, with 100% morbidity in O-AGC Type 2-1 and Type 3-2 and 60% in O-AGC Type 3-0. Chinook salmon exposed toT. dicentrarchishowed characteristic clinical signs of disease in 51% of the challenged population, with 28% morbidity. Common gross pathological signs observed for bothTenacibaculumspecies were congruent with observations on farmed fish in the field, including scale loss, erythematous skin lesion, skin ulcers, fin necrosis, mouth erosion and gill ulceration. Exophthalmia was observed only inT. maritimum-challenged fish, while skin ulcers appeared grossly more severe with exposed musculature inT. dicentrarchi-challenged fish. PureT. maritimumandT. dicentrarchicultures were reisolated from the skin and gills of the challenged fish and their identity was confirmed by species-specific PCR and molecular O-AGC typing. Challenge experiments and associated field surveillance (forT. maritimum) did not show the presence of culturableT. maritimumcells in the anterior kidney. This provides compelling evidence that tenacibaculosis in farmed Chinook salmon is an external infectious disease, and thatTenacibaculumis a marine obligate organism that is unable to survive in fish body fluids and does not cause septicaemia. This has repercussions for approaches to experimental challenges withTenacibaculumspecies, which must occur by immersion rather than intraperitoneal or intramuscular inoculation, to replicate the natural transmission pathway and to ensure a successful challenge model. This study fulfilled modernised Koch’s postulates for the three molecular O-AGC types ofT. maritimumand single strain ofT. dicentrarchias aetiological agents of tenacibaculosis in Chinook salmon that cause mortalities with considerable external abnormalities.Author summaryChinook salmon,Oncorhynchus tshawytscha, is the most significant species of Pacific salmon for its large size and nutritional content which makes it a premium choice for aquaculture. In Aotearoa|New Zealand, Chinook salmon is the only marine salmon species farmed. For a decade, the industry was impacted by an undiagnosed skin disease resulting in high mortalities. Disease susceptibility in Chinook salmon is scarcely studied and added to the challenge for a timely diagnosis. This novel research provides insight on disease susceptibility of Chinook salmon and confirmsTenacibaculumspecies identified in New Zealand pose a high threat to the aquaculture industry. This research has global implications and contributes valuable insights and approaches to disease management that can be applied in British Columbia and Canada where Chinook salmon populations are in decline.

show abstract

“…Thus far, the best protection of the orally delivered antigens from enzymatic cleavage by pepsin and hydrochloric acid at pH values of 2–4, present in the stomach, 33,34 is accomplished by encapsulation with a protective layer of chemical compounds or biological carriers. Several recent publications showed the effectiveness of this approach and reported enhancement of the immune response 35–38 . Currently, there are three main strategies: biopolymers, employment of bacterial cultures and biofilms, and exploitation of fish appetite for crustaceans.…”

Section: Strategies To Increase Oral Vaccines Efficiencymentioning

confidence: 99%

Molecular farming: Expanding the field of edible vaccines for sustainable fish aquaculture

Mičúchová

Piačková

Frébort

et al. 2022

Reviews in Aquaculture

View full text Add to dashboard Cite

Vaccines represent one of the most promising strategies for mitigating economic losses imposed by infectious diseases to global aquaculture. While the majority of commercial vaccines employ injection as the main route of delivery, a substantial body of research explores other avenues for the stimulation of protective immunity. Oral vaccines, representing the most favourable and convenient solution for the aquaculture industry, have been at the forefront of scientific interest for the last couple of decades. The orchestrated effort resulted in identifying the main roadblocks on the path to an ideal edible vaccine and provided several ingenious solutions improving the activation of immunity, ensuring the stability of administered antigens and their uptake upon the passage through the stomach. In the presented review, we describe advances in the available knowledge of the processes prerequisite for developing protective mucosal vaccines and focus readers' attention on the untapped potential of plant‐based production systems in this effort. We propose that these approaches not only meet production demands but also fulfil all requirements of an oral vaccine, addressing all the obstacles, previously solved via separate strategies, in one platform. Thus, combined with the available knowledge of molecular adjuvants and produced for a fraction of the cost, plant‐based production, so‐called molecular farming, is an ideal candidate for vaccine development, paving the road to sustainable aquaculture.

show abstract

Immunogenicity and protective efficacy of Yersinia ruckeri lipopolysaccharide (LPS), encapsulated by alginate-chitosan micro/nanoparticles in rainbow trout (Oncorhyncus mykiss)

Cited by 19 publications

References 44 publications

Alginate microencapsulation of an attenuated O-antigen mutant of Francisella tularensis LVS as a model for a vaccine delivery vehicle

Alginate microencapsulation of an attenuated O-antigen mutant of Francisella tularensis LVS as a model for a vaccine delivery vehicle

Experimental challenge of Chinook salmon withTenacibaculum maritimumandTenacibaculum dicentrarchifulfils Koch’s postulates

Molecular farming: Expanding the field of edible vaccines for sustainable fish aquaculture

Contact Info

Product

Resources

About